IP Library Granted Patent US 10,577,308
Granted Patent B2
US 10,577,308 · App. 15/561,674 · Granted Mar 3, 2020

Sodium channel modulators

Inventors: Spencer John Williams (Coburg, AU); Bevyn Jarrott (Mount Martha, AU)
Assignees: The Florey Institute; The University of Melbourne
C07C217/18C07C217/58C07C233/43C07C255/58C07C311/16C07C311/37C07D213/36C07D231/56C07D239/26C07D271/06C07D401/14C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,308
App. No.
15/561,674
Granted
Mar 3, 2020
Kind
B2
Abstract

The present disclosure relates generally to compounds having activity as voltage-gated sodium channel blockers and their use in the field of therapeutic treatment, including the therapy or management of conditions associated with excessive, unwanted, inadequate or otherwise undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In some embodiments, the disclosure relates to aryloxy-substituted amines for use as sodium channel blockers or modulators. Methods for their manufacture and compositions containing the compounds are also disclosed.

Claims (7)

1. A compound selected from the group consisting of

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound having the formula

or a pharmaceutically acceptable salt or solvate thereof.

3. A composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable additive.

4. A method for preventing sodium ion influx into a cell by blocking or modulating the activity of one or more sodium channel sub-types, said method comprising contacting said cell with the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof.

5. A method for treating a disease or disorder which is mediated by sodium channel activity, in a subject in need thereof, comprising administering to said subject the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the disease or disorder is an epileptic seizure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2018
From: WILLIAMS, SPENCER JOHN
To: THE UNIVERSITY OF MELBOURNE
Reel/Frame 046469/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2018
From: JARROTT, BEVYN
To: THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
Reel/Frame 046469/0735 →
Priority Claims (1)
AU 2015901096 · Mar 26, 2015 · national
Continuity (1)
Related Publication 20180072656A1 · Mar 15, 2018